Bringing Data to Life – Joint Webinar about CytoReason-Ferring Collaboration
CytoReason expands reach in Asia, leveraging ML in drug development for Korean drugmakers
Israel’s CytoReason, S. Korea’s Helixrus partner on machine learning for drug development
Poolbeg signs deal with Cytoreason on influenza drug development
Poolbeg Pharma signs first of its kind AI deal with CytoReason
Pfizer, CytoReason extend AI pact after immune system success
Why Big Pharma is partnering with startups as it becomes more data-driven
Pfizer re-ups CytoReason collab applying AI disease models to drug development
Merck KGaA taps CytoReason’s machine learning platform to profile immuno-oncology drug
Israel’s CytoReason introduces AI clinical drug development platform to Japan’s pharma market
